Is serum complement C1q related to major depressive disorder?

Indian J Psychiatry. 2020 Nov-Dec;62(6):659-663. doi: 10.4103/psychiatry.IndianJPsychiatry_394_19. Epub 2020 Dec 12.

Abstract

Background: Major depressive disorder (MDD) has a high global incidence. While the pathogenesis of depression remains unknown, accumulating evidence has implicated inflammatory changes.

Aim: The aim of the study is to compare the serum complement C1q levels in patients with MDD and healthy controls.

Setting and design: The design was a case-control study.

Materials and methods: Blood samples were collected from the patients with MDD and healthy controls to assess the serum C1q levels using an immunotransmission turbidimetric method.

Statistical analysis: Differences in complement C1q levels between patients with MDD and the controls, as well as between sexes among patients with MDD and the controls, were assessed using Mann-Whitney U-test. Spearman correlations were obtained between complement C1q levels and age.

Results: In total, 1016 participants (508 MDD and 508 controls) were recruited. Differences in the sex ratio (male/female among controls, 181/327; and MDD, 178/330) and age (controls, 47.0 ± 14.9 years; MDD, 46.5 ± 16.5 years) were not significant. The C1q level in the patients with MDD was significantly higher than that in the healthy controls (P < 0.05). In the MDD group, C1q level correlated significantly with age.

Conclusion: Elevation of the serum complement C1q levels in MDD may support the use of C1q as a potential biomarker for diagnosing depression, but further research is needed.

Keywords: Complement C1q; inflammation; major depressive disorder.